

JHMI J09121 A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with CRPC

Description:	The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of = 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide. Eligible patients will have castrate resistant prostate cancer with minimal disease (rising PSA and = 5 total sites of metastases in bone, lymph node and soft tissue) on continuous castrating androgen ablative therapy for = 1 yr; allowed = 2 prior chemo; allowed = 2 prior second line HT; off antiandrogens for = 6weeks
Link:	http://clinicaltrials.gov/ct2/show/NCT01084759
Site:	Johns Hopkins Hospital
Principal Investigator:	Samuel Denmeade, M.D.